financetom
Business
financetom
/
Business
/
DoorDash Narrows Q1 Loss, Revenue Rises -- Shares Drop After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DoorDash Narrows Q1 Loss, Revenue Rises -- Shares Drop After Hours
May 1, 2024 1:42 PM

04:16 PM EDT, 05/01/2024 (MT Newswires) -- DoorDash ( DASH ) reported Q1 net loss Wednesday of $0.06 per diluted share, narrower than a loss of $0.41 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.05.

Revenue for the quarter ended March 31 was $2.51 billion, up from $2.04 billion a year earlier.

Analysts polled by Capital IQ expected $2.45 billion.

Company shares were down more than 10% in recent after-hours activity.

Price: 114.97, Change: -12.41, Percent Change: -9.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Maxeon Announces Restructuring Of Business Portfolio
BRIEF-Maxeon Announces Restructuring Of Business Portfolio
Nov 26, 2024
Nov 26 (Reuters) - Maxeon Solar Technologies Ltd ( MAXN ) : * MAXEON ANNOUNCES RESTRUCTURING OF BUSINESS PORTFOLIO * MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - TO FOCUS EXCLUSIVELY ON U.S. MARKET * MAXEON SOLAR TECHNOLOGIES LTD ( MAXN ) - AGREES TO SELL EMEA, APAC, LATAM SALES TO TCL GROUP * MAXEON SOLAR TECHNOLOGIES LTD ( MAXN...
Theratechnologies Submits Updated Tesamorelin F8 Formulation Application for FDA Review
Theratechnologies Submits Updated Tesamorelin F8 Formulation Application for FDA Review
Nov 26, 2024
08:13 AM EST, 11/26/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Tuesday said it has resubmitted its supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for the F8 formulation of tesamorelin, which has been approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The resubmission addresses...
PyroGenesis Canada Receives $2.8 Million Payment as Part of Existing Contract with Saudi Client
PyroGenesis Canada Receives $2.8 Million Payment as Part of Existing Contract with Saudi Client
Nov 26, 2024
08:10 AM EST, 11/26/2024 (MT Newswires) -- PyroGenesis ( PYRGF ) said Tuesday that it received a $2.8 million payment that is part of an existing $25 million contract for Drosrite aluminum dross recovery systems with Radian Oil and Gas Services, which operates in Saudi Arabia. The payment announced today is made in accordance with a payment schedule that has...
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs
Nov 26, 2024
08:14 AM EST, 11/26/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) and Sarepta Therapeutics ( SRPT ) have struck a global licensing and partnership deal for clinical and preclinical programs in genetic diseases of the muscle, central nervous system, and lungs, the companies said Tuesday. Arrowhead will get an upfront payment of $500 million in cash and $325 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved